Select Publications
Journal articles
2016, 'Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications', Vaccine, 34, pp. 5442 - 5448, http://dx.doi.org/10.1016/j.vaccine.2016.08.057
,2016, 'What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?', Human Vaccines and Immunotherapeutics, 12, pp. 2666 - 2669, http://dx.doi.org/10.1080/21645515.2016.1197449
,2016, 'Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults', PLoS One, 11, pp. e0160446 - e0160446, http://dx.doi.org/10.1371/journal.pone.0160446
,2016, 'Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges', PharmacoEconomics, 34, pp. 723 - 731, http://dx.doi.org/10.1007/s40273-016-0393-0
,2016, 'Assessing the impact of vaccination programmes on burden of disease: Underlying complexities and statistical methods', Vaccine, 34, pp. 3022 - 3029, http://dx.doi.org/10.1016/j.vaccine.2016.04.014
,2016, 'Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks', Health Economics (United Kingdom), 25, pp. 140 - 161, http://dx.doi.org/10.1002/hec.3299
,2016, 'Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical', Vaccine, 34, pp. 320 - 327, http://dx.doi.org/10.1016/j.vaccine.2015.11.053
,2015, 'Risk factors and burden of acute Q fever in older adults in New South Wales: a prospective cohort study', The Medical journal of Australia, 203, pp. 438
,2015, 'Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice', PharmacoEconomics, 33, pp. 1255 - 1268, http://dx.doi.org/10.1007/s40273-015-0309-4
,2015, 'Risk factors and burden of acute Q fever in older adults in New South Wales: A prospective cohort study', Medical Journal of Australia, 203, pp. 438.e1 - 438.e6, http://dx.doi.org/10.5694/mja15.00391
,2015, 'Acute myocardial infarction and influenza: A meta-analysis of case-control studies', Heart, 101, pp. 1738 - 1747, http://dx.doi.org/10.1136/heartjnl-2015-307691
,2015, 'Review of economic evaluations of mask and respirator use for protection against respiratory infection transmission', BMC Infectious Diseases, 15, http://dx.doi.org/10.1186/s12879-015-1167-6
,2015, 'Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested case-control study', Vaccine, 33, pp. 5647 - 5653, http://dx.doi.org/10.1016/j.vaccine.2015.08.068
,2015, 'Risk factors for herpes zoster in a large cohort of unvaccinated older adults: A prospective cohort study', Epidemiology and Infection, 143, pp. 2871 - 2881, http://dx.doi.org/10.1017/S0950268814003653
,2015, 'Medicare Benefits Schedule data to monitor influenza immunisation in Australian adults', Public Health Research and Practice, 25, pp. e2541543, http://dx.doi.org/10.17061/phrp2541543
,2015, 'Factors associated with influenza vaccination in middle and older aged Australian adults according to eligibility for the national vaccination program', Vaccine, 33, pp. 3299 - 3305, http://dx.doi.org/10.1016/j.vaccine.2015.05.046
,2015, 'Control of varicella in the post-vaccination era in Australia: A model-based assessment of catch-up and infant vaccination strategies for the future - CORRIGENDUM', Epidemiology and Infection, 143, pp. 1651, http://dx.doi.org/10.1017/S0950268815000308
,2015, 'A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly', Human Vaccines and Immunotherapeutics, 11, pp. 818 - 825, http://dx.doi.org/10.1080/21645515.2015.1011954
,, 2015, 'Revisiting Styblo's law: Could mathematical models aid in estimating incidence from prevalence data?', Epidemiology and Infection, 143, pp. 1556 - 1565, http://dx.doi.org/10.1017/S0950268814002428
2014, 'Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines"', PharmacoEconomics, 32, pp. 1247, http://dx.doi.org/10.1007/s40273-014-0232-0
,2014, 'Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”', PharmacoEconomics, 32, pp. 1247, http://dx.doi.org/10.1007/s40273-014-0232-0
,2014, 'Control of varicella in the post-vaccination era in Australia: A model-based assessment of catch-up and infant vaccination strategies for the future', Epidemiology and Infection, 760, pp. 1467 - 1476, http://dx.doi.org/10.1017/S0950268814002222
,2014, 'Inaccurate ascertainment of morbidity and mortality due to influenza in administrative databases: A population-based record linkage study', PLoS ONE, 9, pp. e98446, http://dx.doi.org/10.1371/journal.pone.0098446
,2014, 'Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines', PharmacoEconomics, http://dx.doi.org/10.1007/s40273-014-0162-x
,2014, 'Economic evaluations of implemented vaccination programmes: Key methodological challenges in retrospective analyses', Vaccine, 32, pp. 759 - 765, http://dx.doi.org/10.1016/j.vaccine.2013.11.067
,2014, 'Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines', PharmacoEconomics, 32, pp. 525 - 531, http://dx.doi.org/10.1007/s40273-014-0162-x
,2014, 'Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination', Expert Review of Pharmacoeconomics and Outcomes Research, 14, pp. 425 - 435, http://dx.doi.org/10.1586/14737167.2014.908713
,2013, 'Evidence for the aetiology of human papillomavirus in oesophageal squamous cell carcinoma in the Chinese population: a meta-analysis', BMJ Open, 3, pp. e003604 - e003604, http://dx.doi.org/10.1136/bmjopen-2013-003604
,2013, 'Contact Tracing of Tuberculosis: A Systematic Review of Transmission Modelling Studies', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0072470
,2013, 'The Aetiological Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma: A Meta-Analysis', PLoS ONE, 8, pp. e69238 - e69238, http://dx.doi.org/10.1371/journal.pone.0069238
,2013, 'Mortality Attributable to Seasonal and Pandemic Influenza, Australia, 2003 to 2009, Using a Novel Time Series Smoothing Approach', PLoS ONE, 8, pp. e64734 - e64734, http://dx.doi.org/10.1371/journal.pone.0064734
,2013, 'The relationship between human papillomavirus and oesophageal squamous cell carcinoma in China – a review of the evidence', Adv Infect Dis, 3, pp. 17 - 34
,2013, 'Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability', PharmacoEconomics, 31, pp. 693 - 702, http://dx.doi.org/10.1007/s40273-013-0060-7
,2012, 'A systematic review of interventions in primary care to improve health literacy for chronic disease behavioral risk factors', BMC Family Practice, 13, pp. 49, http://dx.doi.org/10.1186/1471-2296-13-49
,2012, 'Economic evaluations of childhood influenza vaccination: A critical review', Pharmacoeconomics, 30, pp. 647 - 660, http://dx.doi.org/10.2165/11599130-000000000-00000
,2012, 'The cost and disease burden of pneumonia in general practice in Australia', Vaccine, 30, pp. 830 - 831, http://dx.doi.org/10.1016/j.vaccine.2011.11.103
,2012, 'Under-explored assumptions in influenza vaccination models: Implications for the universal vaccination of children', Vaccine, 30, pp. 5776 - 5781, http://dx.doi.org/10.1016/j.vaccine.2012.06.067
,2012, 'Which providers can bridge the health literacy gap in lifestyle risk factor modification education: a systematic review and narrative synthesis', BMC Family Practice, 13, pp. 44, http://dx.doi.org/10.1186/1471-2296-13-44
,2011, 'PIN42 Methodological Decisions in Economic Evaluations of Childhood Influenza Vaccination: Findings from a Literature Review', Value in Health, 14, pp. A273 - A273, http://dx.doi.org/10.1016/j.jval.2011.08.229
,2011, 'The potential cost-effectiveness of infant pneumococcal vaccines in Australia', Vaccine, 29, pp. 8077 - 8085, http://dx.doi.org/10.1016/j.vaccine.2011.08.050
,2011, 'Uncertainty and variability in influenza cost-effectiveness models', Australian and New Zealand Journal of Public Health, 35, pp. 576 - 576, http://dx.doi.org/10.1111/j.1753-6405.2011.00788.x
,2010, 'Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies', Emerging Infectious Diseases, 16, pp. 224 - 230, http://dx.doi.org/10.3201/eid1602.090571
,2010, 'Influenza-attributable mortality in Australians aged more than 50 years: A comparison of different modelling approaches', Epidemiology and Infection, 138, pp. 836 - 842, http://dx.doi.org/10.1017/S095026880999118X
,2009, 'Cost effectiveness of influenza vaccination in older adults: A critical review of economic evaluations for the 50- to 64-year age group', Pharmacoeconomics, 27, pp. 439 - 450, http://dx.doi.org/10.2165/00019053-200927060-00001
,2009, 'The burden of rotavirus gastroenteritis in children presenting to a paediatric hospital', Epidemiology and Infection, 137, pp. 943 - 949, http://dx.doi.org/10.1017/S0950268808001520
,, 2008, 'Pappas et al. (2007; 45:883–93)', Clinical Infectious Diseases, 47, pp. 302 - 302, http://dx.doi.org/10.1086/590000
2008, 'Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia (vol 46, pg 1647, 2008)', CLINICAL INFECTIOUS DISEASES, 47, pp. 302 - 302, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000256905000033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2008, 'Influenza-related disease: The cost to the Australian healthcare system', Vaccine, 26, pp. 6818 - 6823, http://dx.doi.org/10.1016/j.vaccine.2008.09.086
,2008, 'Influenza-related hospitalisation and death in Australians aged 50 years and older', Vaccine, 26, pp. 2135 - 2141, http://dx.doi.org/10.1016/j.vaccine.2008.01.051
,2008, 'Mortality benefits of influenza vaccination in elderly people', Lancet Infectious Diseases, 8, pp. 462 - 463, http://dx.doi.org/10.1016/S1473-3099(08)70163-4
,